09726193

6

(FILE 'HOME' ENTERED AT 19:10:23 ON 07 JAN 2003)

FILE 'CAPLUS, USPATFULL, BIOSIS' ENTERED AT 19:11:01 ON 07 JAN 2003

```
L1          3830 S METFORMIN
L2         36456 S SUSTAINED(W)RELEASE
L3           364 S L1 AND L2
L4             7 S L3 AND TMAX
```

blessing

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:464162 CAPLUS
DOCUMENT NUMBER: 131:84333
TITLE: Insecticidal, acaricidal, and bactericidal compositions containing strobilurin and organophosphorus derivatives
INVENTOR(S): Yano, Makio; Hatano, Renpei; Hamamura, Hiroshi
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935914	A1	19990722	WO 1999-JP97	19990114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9918899	A1	19990802	AU 1999-18899	19990114

PRIORITY APPLN. INFO.: JP 1998-20241 19980116
WO 1999-JP97 19990114

AB Novel insecticidal/acaricidal compn., bactericidal compn., and insecticidal/acaricidal/bactericidal compn. each characterized by contg. as the active ingredient a compd. selected from strobilurin-base agents and a compd. selected from organophosphorus agents.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

09726193

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:353262 CAPLUS
DOCUMENT NUMBER: 136:345841
TITLE: Controlled release **metformin** compositions
INVENTOR(S): Chen, Chih-Ming; Cheng, Xiu-Xiu; Jan, Steve; Chou, Joseph
PATENT ASSIGNEE(S): Andrx Corporation, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036100	A1	20020510	WO 2001-US48306	20011030
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030830	A5	20020515	AU 2002-30830	20011030

PRIORITY APPLN. INFO.:
US 2000-705625 A 20001103
US 2000-705630 A 20001103
WO 2001-US48306 W 20011030

AB A compn. and methods thereof for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form contg. preferably a biguanide drug such as **metformin**, on a once-a-day basis. The dosage form provides a mean time to max. plasma concn. (**Tmax**) of the drug which occurs at 5.5 to 7.5 h after oral administration on a one-a-day basis to human patients. Preferably, the dose of drug is administered at dinner time to a patient in the fed state. A tablet core was formulated contg. **metformin**.cntdot.HCl 500, Povidone 36, Na lauryl sulfate 25.8, and Mg stearate 2.8 mg/tablet was coated to have a **sustained -release** coating contg. cellulose acetate 21.5, triacetin 1.3, and PEG-400 2.5 mg/tablet. The coated tablets were laser drilled two holes.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:466311 CAPLUS
DOCUMENT NUMBER: 135:146769
TITLE: Pharmacokinetics of **metformin** gastric-retentive tablets in healthy volunteers
AUTHOR(S): Gusler, G.; Gorsline, J.; Levy, G.; Zhang, S. Z.; Weston, I. E.; Naret, D.; Berner, B.
CORPORATE SOURCE: DepoMed, Inc., Menlo Park, CA, 94025-1436, USA
SOURCE: Journal of Clinical Pharmacology (2001), 41(6), 655-661
CODEN: JCPCBR; ISSN: 0091-2700
PUBLISHER: Sage Publications

blessing

09726193

DOCUMENT TYPE: Journal
LANGUAGE: English
AB The single-dose pharmacokinetics of two gastric-retentive, extended-release tablet formulations of **metformin** hydrochloride in fed, healthy volunteers were compared with those of the currently marketed immediate-release **metformin** hydrochloride product. The plasma concn.-time profiles demonstrated extended-release characteristics from the gastric-retentive tablets. The mean bioavailability from each gastric-retentive tablet was approx. 115%, relative to the immediate-release (IR) product. Cmax values were lower and **tmax** values were greater for the gastric-retentive tablets compared with the IR product. In contrast to conventional extended-release **metformin** tablets reported in the literature, these gastric-retentive tablets showed extended-release plasma concn. profiles of **metformin** hydrochloride and increased bioavailability compared with the immediate-release tablet.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 USPATFULL
ACCESSION NUMBER: 2003:4061 USPATFULL
TITLE: Method of modifying the release profile of **sustained release** compositions
INVENTOR(S): Dasch, James R., Needham, MA, UNITED STATES
Riley, M. Gary I., Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S): Alkermes Controlled Therapeutics, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003004100	A1	20030102	
APPLICATION INFO.:	US 2001-835001	A1	20010413	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1154
AB The present invention relates to a method for the **sustained release** in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a **sustained release** composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the **sustained release** composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.

L4 ANSWER 4 OF 7 USPATFULL
ACCESSION NUMBER: 2002:290588 USPATFULL
TITLE: Biphasic controlled release delivery system for high solubility pharmaceuticals and method
INVENTOR(S): Timmins, Peter, Irby, UNITED KINGDOM
Dennis, Andrew B., Barnston, UNITED KINGDOM
Vyas, Kiren A., Canterbury, UNITED KINGDOM

blessing

09726193

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475521	B1	20021105
APPLICATION INFO.:	US 1999-398107		19990916 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-44446, filed on 19 Mar 1998, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Davis, Stephen B.
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic **metformin** HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram **metformin**, once daily, may be achieved while providing effective control of plasma glucose. The delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules. Methods for forming the so-described biphasic controlled release delivery system and using such biphasic controlled release delivery system for treating diabetes are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 7 USPATFULL
ACCESSION NUMBER: 2002:126046 USPATFULL
TITLE: Controlled release oral tablet having a unitary core
INVENTOR(S): Cheng, Xiu Xiu, Davie, FL, UNITED STATES
Chen, Chih-Ming, Davie, FL, UNITED STATES
Jan, Steve, Coral Springs, FL, UNITED STATES
Chou, Joseph, Coral Springs, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002064556	A1	20020530
	US 6495162	B2	20021217
APPLICATION INFO.:	US 2001-16556	A1	20011101 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-594637, filed on 15 Jun 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Martin P. Endres, Esq., HEDMAN & COSTIGAN, PC., 1185 Avenue of the Americas, New York, NY, 10036

blessing

09726193

NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 7 USPATFULL
ACCESSION NUMBER: 2001:165449 USPATFULL
TITLE: Controlled release **metformin** formulations
INVENTOR(S): Chen, Chih-Ming, Davie, FL, United States
Cheng, Xiu Xiu, Davie, FL, United States
Jan, Steve, Coral Springs, FL, United States
Chou, Joseph, Manassas, VA, United States
PATENT ASSIGNEE(S): Andrx Corporation, Fort Lauderdale, FL, United States, 33314 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001024659	A1	20010927
APPLICATION INFO.:	US 2000-726193	A1	20001129 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-594637, filed on 15 Jun 2000, PENDING Continuation of Ser. No. US 1998-45330, filed on 20 Mar 1998, GRANTED, Pat. No. US 6099859
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Sustained release** pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 7 USPATFULL
ACCESSION NUMBER: 2000:101892 USPATFULL
TITLE: Controlled release oral tablet having a unitary core
INVENTOR(S): Cheng, Xiu Xiu, Davie, FL, United States
Chen, Chih-Ming, Davie, FL, United States
Jan, Steve, Coral Springs, FL, United States
Chou, Joseph, Coral Springs, FL, United States
PATENT ASSIGNEE(S): Andrx Pharmaceuticals, Inc., Fort Lauderdale, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE

blessing

09726193

PATENT INFORMATION:	US 6099859	20000808
APPLICATION INFO.:	US 1998-45330	19980320 (9)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Benston, Jr., William E.	
LEGAL REPRESENTATIVE:	Hedman, Gibson & Costigan, P.C.	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	628	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing

L14 ANSWER 1 OF 34 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V.
ACCESSION NUMBER: 2000:30168511 BIOTECHNO
TITLE: Insulin glargine
AUTHOR: Gillies P.S.; Figgitt D.P.; Lamb H.M.
CORPORATE SOURCE: D.P. Figgitt, Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand. E-mail: demail@adis.co.nz
SOURCE: Drugs, (2000), 59/2 (253-260), 24 reference(s) CODEN: DRUGAY ISSN: 0012-6667
DOCUMENT TYPE: Journal; General Review
COUNTRY: New Zealand
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2000:30168511 BIOTECHNO
AB Insulin glargine is an extended-action biosynthetic human insulin. It precipitates in the neutral environment of subcutaneous tissue and is thus gradually absorbed into the bloodstream. The addition of small amounts of zinc to the formulation further delays absorption. In small euglycaemic clamp studies, the onset of action of insulin glargine was shown to be later, the duration of action longer and the time-action profile flatter than that of Neutral Protamine Hagedorn (NPH) insulin in patients with type 1 diabetes mellitus and healthy volunteers. Four large clinical trials of up to 28 weeks' duration have shown that a single bedtime dose of insulin glargine, in combination with preprandial short-acting insulin, is as effective or more effective than once or twice daily NPH plus short-acting insulin in improving glycaemic control in patients with type 1 diabetes mellitus. In 3 large comparative trials, insulin glargine decreased glycosylated haemoglobin and/or fasting blood glucose levels to a similar extent to that seen with NPH insulin in patients with insulin-dependent or non-insulin-dependent type 2 diabetes mellitus, either as monotherapy or in combination with oral hypoglycaemic agents. Insulin glargine appears to be well tolerated. A lower incidence of hypoglycaemia, especially at night, was reported in most trials with insulin glargine when compared with NPH insulin.

L14 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:282377 CAPLUS
DOCUMENT NUMBER: 138:292793
TITLE: Extended release pharmaceutical composition containing metformin
INVENTOR(S): Murpani, Deepak; Madan, Ashish; Arora, Vinod Kumar; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 18 pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028704	A1	20030410	WO 2002-IB3997	20020927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2001-DE1002 A 20010928

AB The present invention relates to an extended release pharmaceutical compn. contg. metformin and a rate controlling polymer and a process for its prepn. are described. The compn. has a water content of 3.2-10.0% by wt. and improved hardness and friability. For example, tablets with water content of 2.8% were prepd. by conventional dry granulation technique from a blend of metformin hydrochloride 500.0 mg, sodium CM-cellulose 36.0 mg, microcryst. cellulose 60.0 mg, hydroxypropyl Me cellulose 398.0 mg, magnesium stearate 6 mg, and water as needed. Hardness of the tablets obtained was 16.9 Kp and friability was 0.43% by wt. Release of metformin hydrochloride from tablets after 1h, 4 h, 8 h, and 12 h was 27.1%, 58.7%, 84.9%, and 97.8%, resp.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:391499 CAPLUS
DOCUMENT NUMBER: 136:406855
TITLE: Medicine based on antihyperglycemic microcapsules with prolonged release and method for preparing same
INVENTOR(S): Castan, Catherine; Meyrueix, Remi; Soula, Gerard
PATENT ASSIGNEE(S): Flamel Technologies, Fr.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002039984	A2	20020523	WO 2001-FR3625	20011119
WO 2002039984	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2816840	A1	20020524	FR 2000-14876	20001117
AU 2002020796	A5	20020527	AU 2002-20796	20011119

PRIORITY APPLN. INFO.: FR 2000-14876 A 20001117
WO 2001-FR3625 W 20011119

AB The invention concerns an oral galenic form for prolonged release of anti-hyperglycemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 h by overcoming the problems of bypass of the absorption window and the massive localized release of active principles. Therefor, said medicine comprises several thousand anti- hyperglycemic (metformin) microcapsules each consisting of a core comprising at least an anti- hyperglycemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti- hyperglycemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 .mu.. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycemic or hypoglycemic. The invention also concerns the prepn. of said medicine and the use of a

plurality of said microcapsules for making an anti- hyperglycemic medicine. The invention is applicable to the treatment of type II diabetes. A soln. of 159.5 g stearic acid and 159.5 g Et cellulose in 2870 g isopropanol at 50.degree. was sprayed on 700 g of metformin hydrochloride crystals (av. diam. 100-200 .mu.m). The dissoln. rate of the granules thus obtained was 97.1% after 20 min.

L14 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:353262 CAPLUS
DOCUMENT NUMBER: 136:345841
TITLE: Controlled release metformin compositions
INVENTOR(S): Chen, Chih-Ming; Cheng, Xiu-Xiu; Jan, Steve; Chou, Joseph
PATENT ASSIGNEE(S): Andrx Corporation, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036100	A1	20020510	WO 2001-US48306	20011030
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030830	A5	20020515	AU 2002-30830	20011030

PRIORITY APPLN. INFO.:
US 2000-705625 A 20001103
US 2000-705630 A 20001103
WO 2001-US48306 W 20011030

AB A compn. and methods thereof for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form contg. preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to max. plasma concn. (Tmax) of the drug which occurs at 5.5 to 7.5 h after oral administration on a one-a-day basis to human patients. Preferably, the dose of drug is administered at dinner time to a patient in the fed state. A tablet core was formulated contg. metformin.cntdot.HCl 500, Povidone 36, Na lauryl sulfate 25.8, and Mg stearate 2.8 mg/tablet was coated to have a **sustained-release** coating contg. cellulose acetate 21.5, triacetin 1.3, and PEG-400 2.5 mg/tablet. The coated tablets were laser drilled two holes.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:351367 CAPLUS
DOCUMENT NUMBER: 132:352829
TITLE: Pharmaceutical composition for modified release of an insulin sensitizer and another antidiabetic agent
INVENTOR(S): Lewis, Karen; Lilliott, Nicola Jayne; MacKenzie, Donald Colin; Re, Vincenzo
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2

09726193/blessing

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028989	A1	20000525	WO 1999-EP8704	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915285	A	20010807	BR 1999-15285	19991108
EP 1131070	A1	20010912	EP 1999-964483	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529504	T2	20020910	JP 2000-582036	19991108
NO 2001002303	A	20010704	NO 2001-2303	20010510
ZA 2001003843	A	20020514	ZA 2001-3843	20010511
BG 105568	A	20020131	BG 2001-105568	20010607

PRIORITY APPLN. INFO.:		
GB 1998-24866	A	19981112
GB 1998-24867	A	19981112
GB 1998-24869	A	19981112
GB 1999-12190	A	19990525
GB 1999-12191	A	19990525
GB 1999-12193	A	19990525
WO 1999-EP8704	W	19991108

AB A pharmaceutical compn. comprises an insulin sensitizer and another antidiabetic agent and a pharmaceutically acceptable carrier. The compn. is arranged to provide a modified release of at least one of insulin sensitizers and the other antidiabetic. Delayed-release pellets contained a thiazolidinedione 8, glibenclamide 10, microcryst. cellulose 133.5, and lactose monohydrate to 267 mg/capsule.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:260000 CAPLUS
DOCUMENT NUMBER: 132:288772
TITLE: Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
INVENTOR(S): Cottingham, Elizabeth Marie
PATENT ASSIGNEE(S): Children's Hospital Research Foundation, USA; Morrison, John Ainslie
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021522	A1	20000420	WO 1999-US24262	19991015
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6194466	B1	20010227	US 1999-416330	19991012
AU 9964328	A1	20000501	AU 1999-64328	19991015
EP 1121110	A1	20010808	EP 1999-952021	19991015

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:
US 1998-104394P P 19981015
US 1999-416330 A 19991012
WO 1999-US24262 W 19991015

AB A method for minimizing the wt. gain side effect assocd. with psychotropic treatment is disclosed. In the method, Metformin, a biguanide compd., is concurrently administered to a patient taking the psychotropic active. A pharmaceutical compn. contg. the combination of psychotropic active and Metformin is also disclosed. Psychotropic actives are selected from valproate, Risperdal, Lithobid, Zyprexa and Seroquel.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:84280 CAPLUS
DOCUMENT NUMBER: 132:127735
TITLE: Tablets for extended release of a drug in the stomach
INVENTOR(S): Bonhomme, Yves; Nicholson, Geoffroy
PATENT ASSIGNEE(S): LIPHA, Lyonnaise Industrielle Pharmaceutique, Fr.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 976395	A1	20000202	EP 1998-401956	19980730

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

AU 9957318	A1	20000221	AU 1999-57318	19990728
WO 2000006129	A1	20000210	WO 1999-EP5746	19990729

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
EP 1998-401956 A 19980730
WO 1999-EP5746 W 19990729

AB The invention relates to a tablet for extended release of a drug in the stomach, comprising granules of the drug in a hydrophilic matrix, the granules being coated with a coating comprising a source of a carbon dioxide and the coating granules being blended with an agent inducing the release of carbon dioxide and tabletting aids. Granules were formulated contg. metformin.cntdot.HCl 62.42, Methocel K100M 15.9, and PVP K30 4.6 % and the granules were sprayed with PVP K30 1.6 and NaHCO3 12 % and mixed with citric acid 2.1 and Mg stearate 1.22 % for compression to give a

tablet contg. metformin.cntdot.HCl 500 mg/each.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:766143 CAPLUS
DOCUMENT NUMBER: 131:356089
TITLE: Oral immediate- or long-term release metformin-based galenic tablets comprising polyglycolyzated glycerides as an absorption promoters
INVENTOR(S): Saslawski, Olivier; Giet, Philippe; Michel, Dominique; Hulot, Thierry
PATENT ASSIGNEE(S): LIPHA, Lyonnaise Industrielle Pharmaceutique S. A., Fr.
SOURCE: Fr. Demande, 46 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2776189	A1	19990924	FR 1999-7284	19990609

PRIORITY APPLN. INFO.: FR 1999-7284 19990609
AB Oral immediate- or long-term release pharmaceutical tablets contain metformin and polyglycolyzated glycerides having HLB>8 as absorption promoters. An immediate-release pharmaceutical tablet contained calcium acamprosate 47, Gelucire 44/14 39, Labrasol 13, soya lecithin 1% (HLB = 14).

L14 ANSWER 9 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2002333868 EMBASE
TITLE: The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation.
AUTHOR: Woolacott N.F.; Jones L.; Forbes C.A.; Mather L.C.; Sowden A.J.; Song F.J.; Raftery J.P.; Aveyard P.N.; Hyde C.J.; Barton P.M.
CORPORATE SOURCE: N.F. Woolacott, NHS Ctr. for Rev. and Dissemination, University of York, York, United Kingdom
SOURCE: Health Technology Assessment, (2002) 6/16 (236p).
Refs: 522
ISSN: 1366-5278 CODEN: HTASFX
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 040 Drug Dependence, Alcohol Abuse and Alcoholism
036 Health Policy, Economics and Management
038 Adverse Reactions Titles
039 Pharmacy
030 Pharmacology
032 Psychiatry
037 Drug Literature Index
LANGUAGE: English

L14 ANSWER 10 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2002104854 EMBASE
TITLE: Type 2 diabetes therapy: A pathophysiologically based approach.
AUTHOR: Mayerson A.B.; Inzucchi S.E.
CORPORATE SOURCE: Dr. S.E. Inzucchi, Yale University School of Medicine, TMP 534, 333 Cedar St, New Heaven, CT 06520-8020, United

States. silvio.inzucchi@yale.edu
SOURCE: Postgraduate Medicine, (2002) 111/3 (83-95).
Refs: 32
ISSN: 0032-5481 CODEN: POMDAS
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Treatment of type 2 diabetes has become more and more complex as the number of classes of oral antidiabetic agents has increased. Diet, exercise, and the attainment of ideal body weight are the central components of any therapeutic regimen, but most patients are unable to achieve glycemic goals with these measures alone. In this article, Drs Mayerson and Inzucchi review the five classes of available oral antidiabetic agents and discuss their relationship to the pathophysiologic variables that contribute to hyperglycemia in type 2 diabetes.

L14 ANSWER 11 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2001115615 EMBASE
TITLE: Direct-to-consumer advertisements for Glucophage XR.
SOURCE: Medical Letter on Drugs and Therapeutics, (19 Mar 2001) 43/1100 (25-26).
ISSN: 0025-732X CODEN: MELEAP
COUNTRY: United States
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 003 Endocrinology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LANGUAGE: English

L14 ANSWER 12 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2001041059 EMBASE
TITLE: New therapies in diabetes - Thiazolidinediones.
AUTHOR: Smith A.; Fogelfeld L.; Bakris G.
CORPORATE SOURCE: G. Bakris, Rush Medical College, 1700 W Van Buren St., Chicago, IL 60612, United States. gbakris@rush.edu
SOURCE: Emerging Drugs, (2000) 5/4 (441-456).
Refs: 69
ISSN: 1361-9195 CODEN: EMDRFV
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The availability of new classes of oral agents for diabetes opens new prospects and promises in management of diabetes. The current rapid pace of development of new pharmaceutical agents in this field contrasts sharply with the recent past when insulin and first and second generation sulphonylureas were the only drugs available. A decade ago, management of diabetes was characterised by a high degree of frustration among the healthcare providers and their patients. Type 2 diabetes was not well

understood and its main pathophysiological events were not thoroughly defined as they are today. Primary or secondary failure of sulphonylureas medications relegated many patients to therapy with insulin. In many instances high doses of insulin were required which resulted in weight gain that in itself created a further need for more insulin. This vicious cycle created a perception that attainment of glycaemic control in many patients was a difficult if not impossible task. This review will focus on the current management of diabetes with special focus on the class of thiazolidinediones (TZD). It will also illustrate the applications of this new class of drugs in conjunction with other diabetes medications in common clinical scenarios in diabetes.

L14 ANSWER 13 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1999135359 EMBASE
TITLE: Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.
AUTHOR: Fleisher D.; Li C.; Zhou Y.; Pao L.-H.; Karim A.
CORPORATE SOURCE: Dr. D. Fleisher, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-1065, United States. fleisher@umich.edu
SOURCE: Clinical Pharmacokinetics, (1999) 36/3 (233-254). Refs: 185
ISSN: 0312-5963 CODEN: CPKNDH
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Drug-drug, drug-formulation and drug-meal interactions are of clinical concern for orally administered drugs that possess a narrow therapeutic index. This review presents the current status of information regarding interactions which may influence the gastrointestinal (GI) absorption of orally administered drugs. Absorption interactions have been classified on the basis of rate-limiting processes. These processes are put in the context of drug and formulation physicochemical properties and oral input influences on variable GI physiology. Interaction categorisation makes use of a biopharmaceutical classification system based on drug aqueous solubility and membrane permeability and their contributions towards absorption variability. Overlaying this classification it is important to be aware of the effect that the magnitudes of drug dosage and volume of fluid administration can have on interactions involving a solubility rate limits. GI regional differences in membrane permeability are fundamental to the rational development of extended release dosage forms as well as to predicting interaction effects on absorption from immediate release dosage forms. The effect of meals on the regional-dependent intestinal elimination of drugs and their involvement in drug absorption interactions is also discussed. Although the clinical significance of such interactions is certainly dependent on the narrowness of the drug therapeutic index, clinical aspects of absorption delays and therapeutic failures resulting from various interactions are also important.

L14 ANSWER 14 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 97016662 EMBASE
DOCUMENT NUMBER: 1997016662
TITLE: Insulin analogues.
AUTHOR: Barnett A.H.; Owens D.R.
CORPORATE SOURCE: Prof. A.H. Barnett, Department of Medicine, University of Birmingham, Birmingham Heartlands Hosp NHS Trust, Birmingham B9 5SS, United Kingdom

09726193/blessing

SOURCE: Lancet, (1997) 349/9044 (47-51).
Refs: 39
ISSN: 0140-6736 CODEN: LANCAO
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
030 Pharmacology
037 Drug Literature Index
039 Pharmacy
038 Adverse Reactions Titles
LANGUAGE: English

L14 ANSWER 15 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 96189161 EMBASE
DOCUMENT NUMBER: 1996189161
TITLE: Endocrinology.
AUTHOR: Watts N.B.; Blevins Jr. L.S.
CORPORATE SOURCE: Emory University School of Medicine,Atlanta, GA, United States
SOURCE: Journal of the American Medical Association, (1996) 275/23 (1806-1807).
ISSN: 0098-7484 CODEN: JAMAAP
COUNTRY: United States
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 003 Endocrinology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

L14 ANSWER 16 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95116075 EMBASE
DOCUMENT NUMBER: 1995116075
TITLE: [Pro and contra: The 'wonder pill' metformin?].
PRO UND CONTRA: 'WUNDERPILLE' METFORMIN?.
AUTHOR: Hasselkus W.; Chanteleau E.
CORPORATE SOURCE: In der Au 20,96472 Rodental, Germany
SOURCE: Zeitschrift fur Allgemeinmedizin, (1995) 71/7 (550+553-555).
ISSN: 0341-9835 CODEN: ZALMAS
COUNTRY: Germany
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 003 Endocrinology
020 Gerontology and Geriatrics
028 Urology and Nephrology
048 Gastroenterology
037 Drug Literature Index
LANGUAGE: German
SUMMARY LANGUAGE: German

L14 ANSWER 17 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95053488 EMBASE
DOCUMENT NUMBER: 1995053488
TITLE: [Metformin therapy in type II diabetics: Physiological answer to the metabolic syndrome].
METFORMINTHERAPIE BEI TYP-II-DIABETIKERN. PHYSIOLOGISCHE ANTWORT AUF DAS METABOLISCHE SYNDROM.
AUTHOR: Hasselkus W.
CORPORATE SOURCE: Friedrich-Alexander Universitat, Erlangen-Nurnberg, In der Au 20,96472 Rodental, Germany
SOURCE: Therapiewoche, (1995) 45/3 (172-174+176-177).
ISSN: 0040-5973 CODEN: THEWA6

09726193/blessing

COUNTRY: Germany
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
037 Drug Literature Index
LANGUAGE: German
SUMMARY LANGUAGE: English; German
AB Elevation of lactate by therapy with Metformin is dependant on the dosage well as on the renal elimination. Non retarded Metformin has a quicker renal elimination as the retarded form. Therapy with non-retarded Metformin 500 mg represents a significant improvement compared with the usual therapy with retarded Metformin 850 mg. Also, obese type II diabetics, much older than 65 years, can be treated without problems with metformin 500 mg if their creatinin-clearance is above 50 ml/min.

L14 ANSWER 18 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 91113255 EMBASE
DOCUMENT NUMBER: 1991113255
TITLE: Bezafibrate retard in type II diabetic patients: Effects on hemostasis and glucose homeostasis.
AUTHOR: Mikhailidis D.P.; Mathur S.; Barradas M.A.; Dandona P.
CORPORATE SOURCE: Department Chemical Pathology, Human Metabolism, Royal Free Hospital, Pond Street,London NW3 2QG, United Kingdom
SOURCE: Journal of Cardiovascular Pharmacology, (1991) 16/SUPPL. 9 (S26-S29).
ISSN: 0160-2446 CODEN: JCPCDT
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
025 Hematology
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
AB A double-blind, placebo-controlled trial assessed the effect of a slow-release formulation of bezafibrate (Bezalip Mono, 400 mg daily for 3 months) on lipid profile, glucose homeostasis, platelet function, and plasma fibrinogen concentration in non-insulin-dependent (type II) diabetics. Twenty-four patients completed the trial. There was a significant improvement in the cholesterol ($p < 0.02$), triglyceride ($p < 0.01$), and nonesterified fatty acid ($p < 0.05$) concentrations and in the fasting blood glucose ($p < 0.03$) and glycosylated hemoglobin ($p < 0.01$) levels of those ($n = 11$) who received the active preparation but not in those ($n = 13$) who received placebo. Treatment, but not placebo, also resulted in a significant ($p < 0.01$) fall in plasma fibrinogen concentration and a trend towards inhibition of platelet aggregation. Bezafibrate was well tolerated; only one patient (not included in the analysis of results) withdrew from the trial possibly because of side effects of the drug. A larger study is needed to establish whether bezafibrate can reduce nonlipid risk factors (e.g., plasma fibrinogen concentration, glucose intolerance, and hyperinsulinemia) in normo- and hyperlipidemic subjects.

L14 ANSWER 19 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 90369124 EMBASE
DOCUMENT NUMBER: 1990369124
TITLE: Tablets produced under licence. Do they have the same dissolution characteristics and drug content uniformity as the original ones? Example: Metformin hydrochloride **sustained-release** tablets.

09726193/blessing

AUTHOR: Saleh S.I.
CORPORATE SOURCE: Faculty of Pharmacy, Assiut University, Assiut, Egypt
SOURCE: Sciences Techniques et Pratiques Pharmaceutiques, (1990) 6/8 (598-603).
ISSN: 0758-6922 CODEN: STPPEF
COUNTRY: France
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: English

L14 ANSWER 20 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 90359101 EMBASE
DOCUMENT NUMBER: 1990359101
TITLE: Bedtime administration of metformin may reduce insulin requirements.
AUTHOR: Ravina A.; Minuchin O.
CORPORATE SOURCE: Diabetes Department, Linn Central Clinic, Haifa, Israel
SOURCE: Harefuah, (1990) 119/7-8 (200-203+247).
ISSN: 0017-7768 CODEN: HAREA6
COUNTRY: Israel
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 003 Endocrinology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: Hebrew
SUMMARY LANGUAGE: English

L14 ANSWER 21 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 87027164 EMBASE
DOCUMENT NUMBER: 1987027164
TITLE: [Treatment of acute poisoning with a biguanide derivative (metformin)].
INTOXICATION AIGUE PAR UN BIGUANIDE (METFORMINE) CONDUITE THERAPEUTIQUE.
AUTHOR: Huguet C.; Lanotte R.; Ged E.; et al.
CORPORATE SOURCE: Service de Reanimation Medicale Adultes, CHR Bretonneau, 37044 Tours Cedex, France
SOURCE: Revue de Medecine de Tours, (1986) 20/8 (521-524).
CODEN: RMDTC7
COUNTRY: France
DOCUMENT TYPE: Journal
FILE SEGMENT: 038 Adverse Reactions Titles
037 Drug Literature Index
052 Toxicology
LANGUAGE: French

L14 ANSWER 22 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 80112791 EMBASE
DOCUMENT NUMBER: 1980112791
TITLE: Comparison of in-vitro release and renal elimination of 1-butylbiguanide from timed-release oral antidiabetic preparations.
AUTHOR: Grdinic S.; Gjuris V.; Bican-Fister T.
CORPORATE SOURCE: Inst. Contr. Drugs, Zagreb, Yugoslavia
SOURCE: Acta Pharmaceutica Jugoslavica, (1979) 29/4 (215-221).
CODEN: APJUA8
COUNTRY: Yugoslavia
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: Serbo-Croatian

L14 ANSWER 23 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 76127433 EMBASE
DOCUMENT NUMBER: 1976127433
TITLE: [Result of diabetotherapy with Glucophage retard].
ERGEBNIS DER DIABETESBEHANDLUNG MIT GLUCOPHAGE RETARD.
AUTHOR: Beyer G.
CORPORATE SOURCE: Falkensteiner Str. 16, Hof/Moschendorf, Germany
SOURCE: Therapie der Gegenwart, (1975) 114/9 (1426-1437).
CODEN: THGEAU
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
003 Endocrinology
LANGUAGE: German

L14 ANSWER 24 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 76045617 EMBASE
DOCUMENT NUMBER: 1976045617
TITLE: [A delayed action formulation of phenformin in treatment of diabetes].
ERFAHRUNGEN MIT DB RETARD IN DER THERAPIE DES DIABETIKERS.
AUTHOR: Grujic M.; Perinovic M.
CORPORATE SOURCE: I. Klin. Inn. Med., Med. Fak., Sarajevo, Yugoslavia
SOURCE: Medizinische Welt, (1975) 26/12 (571-573).
CODEN: MEWEAC
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
003 Endocrinology
LANGUAGE: German
AB The authors consider phenformin a suitable biguanide to repolarize the metabolism of carbohydrates in obese diabetic adults where diet alone is insufficient for control of blood sugar levels. The use of phenformin in combination with insulin allows a reduction in the size of the insulin dose.

L14 ANSWER 25 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 76045611 EMBASE
DOCUMENT NUMBER: 1976045611
TITLE: [Proinsulin and insulin secretion in overweight women before and after metformin administration].
PROINSULIN- UND INSULINSEKRETION BEI UBERGEWICHTIGEN FRAUEN VOR UND NACH GABE VON METFORMIN.
AUTHOR: Hausmann L.; Schubotz R.
CORPORATE SOURCE: Med. Poliklin., Univ. Marburg/L., Germany
SOURCE: Arzneimittel-Forschung/Drug Research, (1975) 25/4 (668-675).
CODEN: ARZNAD
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
030 Pharmacology
003 Endocrinology
LANGUAGE: German
AB In 49 normal and overweight women, the basal and reactive proinsulin and insulin level as well as serum cholesterol and triglycerides were determined before and after the application of N,N dimethylbiguanide hydrochloride (metformin, 'Glucophage retard'). The proinsulin fraction of the basal total insulin is 70% in normal women. With increasing overweight the percentage of proinsulin decreases in favor of insulin. Stimulation with 100 g oral glucose, in analogy to the total insulin, significantly increased proinsulin levels, remaining, however, below the insulin levels. Accordingly the increased secretion of total insulin in overweight persons consists mostly of insulin and to a lesser degree of proinsulin.

Additionally there exists a significant correlation between the triglycerides and the degree of overweight. After 4 wk application of 1.7 g metformin daily the weight reduction reached on an average 1.4 kg, after 15 wk 5.2 kg. In relation to the weight reduction lower proinsulin and insulin levels were noticed before and after stimulation with glucose. Even those test persons who did not lose weight under metformin showed lower proinsulin and insulin levels. It might be that metformin leads to a slow down in glucose absorption and as a consequence to a decrease of insulin secretion. Lower triglyceride values after treatment with metformin not only were a sign of weight reduction: biguanides also influence the fat metabolism independently of the carbohydrate metabolism. Additional to the reduction diet the treatment with metformin seems to be very appropriate for overweighty patients with hyperinsulinism and hypertriglyceridemia.

L14 ANSWER 26 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 75126455 EMBASE
DOCUMENT NUMBER: 1975126455
TITLE: [Investigation for the improvement of biguanide tolerance]. RECHERCHE D'AMELIORATION DE LA TOLERANCE AUX BIGUANIDES.
AUTHOR: Puech H.
CORPORATE SOURCE: Hop. St Joseph, Paris, France
SOURCE: ENTRET.BICHAT-THER., (1974) (277-280).
CODEN: XXXXXB
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
006 Internal Medicine
030 Pharmacology
LANGUAGE: French

L14 ANSWER 27 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 75026863 EMBASE
DOCUMENT NUMBER: 1975026863
TITLE: [Treatment of diabetes mellitus with biguanides]. DIE BEHANDLUNG DES DIABETES MELLITUS MIT BIGUANIDEN.
AUTHOR: Oberdisse K.
CORPORATE SOURCE: Schlossmannstr. 32, Dusseldorf, Germany
SOURCE: Therapiewoche, (1974) 24/23 (2688-2700).
CODEN: THEWA6
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: German

L14 ANSWER 28 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 74209345 EMBASE
DOCUMENT NUMBER: 1974209345
TITLE: [Clinical examination of metformin (Glucophage retard) in 50 overweight diabetic adults]. KLINISCHE PRUFUNG VON GLUCOPHAGE RETARD BEI 50 STABILEN, UBERGEWICHTIGEN ERWACHSENENDIABETIKERN.
AUTHOR: Kopp H.
CORPORATE SOURCE: Med. Abt., Hessenklin., Erbach/Odenwald, Germany
SOURCE: Medizinische Welt, (1974) 25/15 (658-660).
CODEN: MEWEAC
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
003 Endocrinology
006 Internal Medicine
030 Pharmacology
LANGUAGE: German

09726193/blessing

L14 ANSWER 29 OF 34 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 74141873 EMBASE
DOCUMENT NUMBER: 1974141873
TITLE: A clinical evaluation of a delayed release preparation of metformin.
AUTHOR: Campbell I.W.; Clarke B.F.; Duncan L.J.P.
CORPORATE SOURCE: Diab. Dietet. Dept., Roy. Infirm., Edinburgh, United Kingdom
SOURCE: J.INT.MED.RES., (1973) 1/6 (551-556).
CODEN: XXXXXB
DOCUMENT TYPE: Journal
FILE SEGMENT: 038 Adverse Reactions Titles
037 Drug Literature Index
030 Pharmacology
LANGUAGE: English

L14 ANSWER 30 OF 34 USPATFULL
ACCESSION NUMBER: 2002:290588 USPATFULL
TITLE: Biphasic controlled release delivery system for high solubility pharmaceuticals and method
INVENTOR(S): Timmins, Peter, Irby, UNITED KINGDOM
Dennis, Andrew B., Barnston, UNITED KINGDOM
Vyas, Kiren A., Canterbury, UNITED KINGDOM
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475521	B1	20021105
APPLICATION INFO.:	US 1999-398107		19990916 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-44446, filed on 19 Mar 1998, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Davis, Stephen B.
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1674
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose. The delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules. Methods for forming the so-described biphasic controlled release delivery system and using such biphasic controlled release delivery system for treating diabetes are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 31 OF 34 USPATFULL

ACCESSION NUMBER: 2002:81525 USPATFULL

TITLE: Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia

INVENTOR(S): Bonhomme, Yves, Charbonnieres les Bains, FRANCE
Briet, Philippe, Lyons, FRANCE

PATENT ASSIGNEE(S): Merck Patent Gesellschaft mit beschrankter Haftung, Darnstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6372790	B1	20020416	
	WO 9940904		19990819	
APPLICATION INFO.:	US 2000-601618		20001130	(9)
	WO 1999-EP614		19990130	
			20001130	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-1709	19980212

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Millen, White, Zelano & Branigan, P.C.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising: (i) metformin, optionally in the form one of its pharmaceutically acceptable salts; (ii) a fibrate selected from fenofibrate and bezafibrate; and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of non-insulin-dependent diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 32 OF 34 USPATFULL

ACCESSION NUMBER: 2001:29618 USPATFULL

TITLE: Use of metformin to counteract weight gain associated with valproate and other psychotropic medications

INVENTOR(S): Cottingham, Elizabeth Marie, 300 Warren Ave., Cincinnati, OH, United States 45219
Morrison, John Ainslie, 3740 Clifton Ave., Cincinnati, OH, United States 45220

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6194466	B1	20010227	
APPLICATION INFO.:	US 1999-416330		19991012	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104394P	19981015 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
ASSISTANT EXAMINER: Kim, J.
LEGAL REPRESENTATIVE: Frost Brown Todd LLC

09726193/blessing

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for minimizing the weight gain side effect associated with Valproate treatment is disclosed. In this method, Metformin, a biguanide compound, is concurrently administered to a patient taking the Valproate therapy. A pharmaceutical composition containing the combination of Valproate and Metformin is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 33 OF 34 USPATFULL
ACCESSION NUMBER: 2000:101895 USPATFULL
TITLE: Oral dosage form for the controlled release of a biguanide and sulfonylurea
INVENTOR(S): Chen, Chih-Ming, Davie, FL, United States
Cheng, Xiu Xiu, Davie, FL, United States
Chou, Joseph, Coral Springs, FL, United States
Jan, Steve, Coral Springs, FL, United States
PATENT ASSIGNEE(S): ANDRX Corporation, Fort Lauderdale, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6099862		20000808
APPLICATION INFO.:	US 1998-143876		19980831 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Seidleck, Brian K.
LEGAL REPRESENTATIVE: Hedman, Gibson & Costigan, P.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A controlled release pharmaceutical tablet containing antihyperglycemic drug and a hypoglycemic drug that does not contain an expanding or gelling polymer layer and comprising a core containing the antihyperglycemic drug and the hypoglycemic drug, a semipermeable coating membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the core.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 34 OF 34 USPATFULL
ACCESSION NUMBER: 71:42732 USPATFULL
TITLE: METHOD AND COMPOSITIONS FOR TREATMENT OF MENTAL ILLNESS
INVENTOR(S): Scott, John F., Poole, England
PATENT ASSIGNEE(S): Jan Marcel Didier Aron-Samuel, Suresness, France

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3621097		19711116
APPLICATION INFO.:	US 1970-24034		19700330 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1968-732832, filed on 29 May 1968, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1967-108558	19670602

09726193/blessing

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
LEGAL REPRESENTATIVE: Brown; John M., Kolano; John J., Schubert; Elliot N., Ramm; Walter C., Wegner; Helmuth A.
NUMBER OF CLAIMS: 4
LINE COUNT: 473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the treatment of mental illness comprising the administration of dimethyl biguanide of the formula ##SPC1##

To an animal receiving an ataractic. A pharmaceutical composition comprising dimethyl biguanide and an ataractic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.